Apolipoprotein B Monoclonal Antibody (F2C9)

Product Details	
Size	1 mg
Species Reactivity	Human
Published Species	Human
Host/Isotype	Mouse / IgG1
Class	Monoclonal
Type	Antibody
Clone	F2C9
Conjugate	Unconjugated
Immunogen	Purified human serum LDL
Form	Liquid
Concentration	5 mg/mL
Purification	Protein A
Storage buffer	PBS, pH 7.4
Contains	0.09% sodium azide
Storage conditions	Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C
RRID	AB_11152638

Applications	Tested Dilution	Publications
Western Blot (WB)	2 µg/mL	1 Publication
Immunocytochemistry (ICC/IF)	2-4 µg/mL	-
ELISA (ELISA)	Assay-dependent	-
Immunoprecipitation (IP)	Assay-dependent	-
Radioimmune Assays (RIA)	Assay-dependent	-

Product Specific Information

MIA1609 targets Apolipoprotein B in ELISA, IP and RIA applications and shows reactivity with Human samples.

The MIA1609 immunogen is purified human serum LDL.

MIA1609 detects Apolipoprotein B which has a predicted molecular weight of approximately 502 kDa.

MIA1609 was formerly sold as a Seradyn product.

Product Images For Apolipoprotein B Monoclonal Antibody (F2C9)



Apolipoprotein B Antibody (MIA1609) in ICC/IF
Immunofluorescence analysis of Apolipoprotein B was performed using 70% confluent log phase Hep G2 cells. The cells were fixed with 4% paraformaldehyde for 5 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 2% BSA for 45 minutes at room temperature. The cells were labeled with Apolipoprotein B Monoclonal Antibody (F2C9) (Product # MIA1609) at 4 µg/mL concentration in 0.1% BSA, incubated at 4 degree celsius overnight and then labeled with Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 (Product # A32766), (1: 2000 dilution), for 45 minutes at room temperature (Panel a: Green). Nuclei (Panel b: Blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c: Red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasm localization. Panel e represents negative cell line U-87 MG. Panel f represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.



Apolipoprotein B Antibody (MIA1609)
Antibody specificity was demonstrated by detection of differential basal expression of the target across cell models owing to their inherent genetic constitution. Immunofluorescence analysis using Anti-Apolipoprotein B Monoclonal Antibody (F2C9) (Product # MIA1609), shows expression in Hep G2 compared to U-87 MG. {RE}



Apolipoprotein B Antibody (MIA1609) in ICC/IF
Immunofluorescence analysis of Apolipoprotein B was performed using 70% confluent log phase Hep G2 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 2% BSA for 1 hour at room temperature. The cells were labeled with Apolipoprotein B (F2C9) Mouse Monoclonal Antibody (Product # MIA1609) at 2 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A28175) a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasmic localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.

View more figures on thermofisher.com

1 Reference

Western Blot (1)

Biomedicines

Mass-Spectrometry Based Proteome Comparison of Extracellular Vesicle Isolation Methods: Comparison of ME-kit, Size-Exclusion Chromatography, and High-Speed Centrifugation.

"MIA1609 was used in Western Blotting to evaluate three EV isolation methods on plasma for their applicability in clinical proteomics and biomarker discovery."

Authors: Askeland A,Borup A,Østergaard O,Olsen JV,Lund SM,Christiansen G,Kristensen SR,Heegaard NHH, Pedersen S

Year
2020

Species
Human

Dilution
1:1000